Status:
COMPLETED
Tolerability/PoP Study in Allergic Rhinitis After Intranasal Administration of AZD8848
Lead Sponsor:
AstraZeneca
Conditions:
Allergic Rhinitis
Eligibility:
MALE
18-45 years
Phase:
PHASE1
Brief Summary
The primary purpose is to investigate tolerability/safety of repeated weekly doses of AZD8848 administered intranasally to seasonal allergic rhinitis patients.
Eligibility Criteria
Inclusion
- Patients with a history of birch and/ or timothy grass pollen induced seasonal allergic rhinitis for at least the previous 2 years (verified by a positive skin prick test)
- Patients with need of treatment for their nasal symptoms during the pollen season
Exclusion
- Clinical relevant disease or abnormality (past or present) - other than allergic rhinitis
- Symptomatic perennial allergic or non-allergic rhinitis
- A history of asthma
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2010
Estimated Enrollment :
103 Patients enrolled
Trial Details
Trial ID
NCT00770003
Start Date
September 1 2008
End Date
February 1 2010
Last Update
August 14 2015
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Helsingborg, Sweden
2
Research Site
Lund, Sweden